<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antipsychotics for initial management of the acutely agitated adult patient with psychosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antipsychotics for initial management of the acutely agitated adult patient with psychosis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antipsychotics for initial management of the acutely agitated adult patient with psychosis</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="10%"></colgroup><colgroup width="30%"></colgroup> <tbody> <tr> <td class="subtitle1_left"> </td> <td class="subtitle1_left">Formulation</td> <td class="subtitle1_left">Route</td> <td class="subtitle1_left">Initial dose (mg)</td> <td class="subtitle1_left">Frequency (hours)</td> <td class="subtitle1_left">Maximum initial dose per 24 hours (mg)</td> <td class="subtitle1_left">Time to peak plasma concentration (hours)</td> <td class="subtitle1_left">Notes</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Second-generation agents</td> </tr> <tr> <td class="indent1" rowspan="2">Olanzapine</td> <td>Injection (short-acting)</td> <td>IM, IV<sup>*</sup></td> <td>5 to 10<sup>¶</sup></td> <td>2 to 4<sup>Δ</sup></td> <td>30 (including oral doses)</td> <td>0.25 to 0.75</td> <td rowspan="2"> <ul> <li>Onset of action IM: Approximately 15 minutes; IV: 5 to 10 minutes.</li> <li>If given IM/IV with parenteral benzodiazepine there is increased risk of excess sedation and respiratory depression; separating doses by ≥60 minutes suggested.</li> <li>Decreased clearance in female and/or non-smoking patients; consider use of lower doses in range.</li> <li>Moderate dose related QTc prolongation; some data suggest mild effect.</li> </ul> </td> </tr> <tr> <td>Disintegrating tablet</td> <td>Oral, SL</td> <td>5 to 10</td> <td>2</td> <td>20 (including IM/IV doses)</td> <td>5</td> </tr> <tr> <td class="indent1">Risperidone</td> <td>Disintegrating tablet, oral solution</td> <td>Oral</td> <td>1 to 2</td> <td>0.5 to 2</td> <td>6</td> <td>1.5</td> <td> <ul> <li>Onset of action (oral disintegrating tablet): 70 minutes on average.</li> <li>Decreased clearance in kidney and/or hepatic impairment.</li> <li>Moderate dose related QTc prolongation.</li> <li>Metabolized by CYP2D6; variable efficacy due to genetic polymorphisms.</li> </ul> </td> </tr> <tr> <td class="indent1">Ziprasidone</td> <td>Short-acting mesylate injection</td> <td>IM</td> <td>10 to 20</td> <td>2 to 4</td> <td>40</td> <td>0.5 to 1</td> <td> <ul> <li>Dose related QTc prolongation and risk of cardiac dysrhythmias; risk appears greater than other second-generation agents.</li> <li>Onset of action IM: 15 to 20 minutes.</li> <li>Oral preparation available.</li> </ul> </td> </tr> <tr> <td class="indent1">Aripiprazole</td> <td>Disintegrating tablet, oral solution</td> <td>Oral</td> <td>10 to 15</td> <td>2</td> <td>30</td> <td>3 to 5</td> <td> <ul> <li>Less sedating. Minimal prolongation of QTc interval or orthostatic hypotension.</li> <li>Metabolized by CYP2D6; variable efficacy due to genetic polymorphisms.</li> <li>Refer to UpToDate topic on choosing treatment for severe postpartum unipolar major depression.</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="8">First-generation agents</td> </tr> <tr> <td class="indent1" rowspan="2">Haloperidol</td> <td>Short-acting lactate injection</td> <td>IM, IV</td> <td>2 to 10</td> <td>0.5 to 2<sup>Δ</sup></td> <td>20<sup>◊</sup></td> <td>0.5 to 1</td> <td rowspan="2"> <ul> <li>Onset of action IM/IV: 30 to 60 minutes.</li> <li>Sedation, hypotension, and prolongation of QTc interval more pronounced with injection.</li> <li>Increased risk of acute dystonic reaction.<sup>§</sup></li> <li>For severe agitation, typically initial dose is 5 mg IM/IV combined with a benzodiazepine (eg, lorazepam 2 mg IM/IV).</li> <li>Older adults should start with a lower initial dose (1 to 2 mg orally).</li> </ul> </td> </tr> <tr> <td>Oral solution</td> <td>Oral</td> <td>2 to 10</td> <td>6</td> <td>30</td> <td>2</td> </tr> <tr> <td class="indent1">Droperidol</td> <td>Injection (short-acting)</td> <td>IM, IV</td> <td>2.5 to 10</td> <td>2 to 4<sup>Δ</sup></td> <td>40</td> <td>0.5</td> <td> <ul> <li>Rapid onset of 3 to 10 minutes advantageous in severely agitated violent patients.</li> <li>Dose related QTc prolongation and risk of cardiac dysrhythmias.</li> <li>For severe agitation, typically initial dose is 2.5 to 5 mg IM/IV combined with a benzodiazepine (eg, midazolam 2.5 to 5 mg IM/IV).</li> <li>Increased risk of acute dystonic reaction.<sup>§</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>The approach to pharmacologic treatment of the acutely agitated patient, including specific medication choices and combinations depending upon presentation (eg, toxic ingestion, withdrawal syndrome, or known psychiatric history) is provided in the accompanying topic reviews and in an algorithm.</li>
<li>Antipsychotics should be avoided in patients with anticholinergic delirium or acute alcohol withdrawal; refer to UpToDate topic. Dose reduction by one-half is needed for older adults, debilitated patients, and if used in combination with other sedation.</li>
<li>Refer to accompanying text for discussion of electrocardiograph and other monitoring for agents known to cause prolongation of the QTc interval.</li>
<li>Antipsychotics (eg, aripiprazole, risperidone, haloperidol) are metabolized to varying degrees by CYP450 2D6, 3A4, and/or substrates of P-glycoprotein. Drug interactions and additive QTc prolongation effects can be assessed by use of the <a href="https://www.uptodate.com/drug-interactions">drug interactions program</a> included within UpToDate.</li>
</ul></div><div class="graphic_footnotes"><p>IM: intramuscular; IV: intravenous; SL: sublingual.</p>
<p>* IV administration of olanzapine should be limited to settings where patient can be closely monitored for respiratory depression and excessive sedation.</p>
<p>¶ If olanzapine is administered IV, limit total dose to 10 mg per episode (ie, if initial dose was &lt;10 mg, may repeat with additional dose after ≥10 minutes up to 10 mg total).</p>
<p>Δ It may be necessary to repeat initial dose or fraction thereof after 15 to 20 minutes in patients with severe agitation until desired level of sedation attained.</p>
<p>◊ Selected patients without schizophrenia may need a higher cumulative haloperidol dose (eg, up to 30 mg) during the first 24 hours of treatment to achieve and maintain adequate sedation.</p>
§ Treatment of acute dystonic reactions is diphenhydramine 25 to 50 mg IM/IV or benztropine 1 to 2 mg IM/IV, which is discussed in detail separately.</div><div id="graphicVersion">Graphic 60846 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
